R. Valgardsdottir et al., GENOMIC INSTABILITY AND POOR-PROGNOSIS ASSOCIATED WITH ABNORMAL TP53 IN BREAST CARCINOMAS - MOLECULAR AND IMMUNOHISTOCHEMICAL ANALYSIS, APMIS. Acta pathologica, microbiologica et immunologica Scandinavica, 105(2), 1997, pp. 121-130
Alterations of the TP53 gene were analyzed in samples from 87 primary
breast cancer patients, using molecular and immunohistochemical approa
ches. Mutations were detected in 17% of the samples, using polymerase
chain reaction (PCR) and constant denaturant gel electrophoresis (CDGE
) on exons 5-8 of the TP53 gene, and were confirmed by sequencing. Abn
ormal TP53 protein staining was found in 55% of the primary samples, u
sing the monoclonal TP53 antibody DO7. A statistically significant ass
ociation was found between TP53 mutations and abnormal protein stainin
g (p=0.002). Our results suggest that dysfunction of the TP53 protein
is associated with tumor progression, as we found an association betwe
en TP53 abnormalities and accumulation of genetic lesions, measured as
overall allelic imbalance (AI), homogeneously staining regions (HSR)
and strong ERBB2 overexpression. Furthermore, patients with TP53 mutat
ion had a highly elevated risk of dying from breast cancer during the
study period (p<0.001, RR=10.68) at a median follow-up time of 42 mont
hs. Abnormal TP53 staining was much more frequent than the mutations,
but it was not of prognostic significance, whereas strong staining was
an independent prognostic factor. We therefore conclude that loss of
functional TP53 leads to genetic instability, resulting in poorer shor
t-term prognosis, and that only strong staining of TP53, and not abnor
mal protein staining in general, is of prognostic significance.